Stay updated with breaking news from Stephenc Glover. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZyVersa Therapeutics shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for inhibiting ASC with IC 100 to potentially attenuate cardiac comorbidities in patients with Alzheimer's Disease.
Inhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality....
Stephen C. Glover, co-founder, chairman, CEO and president of ZyVersa Therapeutics Inc. ZVSA, was recently a panelist at Benzinga's Virtual HealthCare Summit…
In obesity, inflammasome activation in fat tissue triggers cell death and release of inflammatory cytokines & ASC Specks, spreading damaging inflammation....
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease...